AI assistant
Cipla Ltd. Capital/Financing Update 2025
59275_rns_2025-07-21_f37ae3b5-3b4a-4bbe-8922-4bc16a8efad6.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
21st July, 2025
- (1) BSE Limited Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001
- (2) National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: CIPLA EQ
Scrip Code: 500087
(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg
Sub: Acquisition of securities in iCaltech Innovations Private Limited
Dear Sir/Madam,
Pursuant to the provisions of the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that the Company has entered into definitive agreements to acquire 20% voting rights in iCaltech Innovations Private Limited.
The details required to be disclosed under the Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 on the captioned subject are enclosed to this intimation as Annexure I.
A copy of press release for the said investment is enclosed as Annexure II.
Please take the above information on record.
Yours faithfully, For Cipla Limited RAJEND RA CHOPRA Digitally signed by RAJENDRA CHOPRA Date: 2025.07.21 19:05:47 +05'30'
Rajendra Chopra Company Secretary
Prepared by: Mandar Kurghode
Cipla Ltd.
Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 F +91 22 41916120 W www.cipla.com E-mail [email protected] Corporate Identity Number L24239MH1935PLC002380
Annexure - I Details as per the SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024
| Sr. No. | Particulars | Details |
|---|---|---|
| a) | Name of the target entity, details in | Name of the target entity: iCaltech Innovations Private |
| brief such as size, turnover etc. | Limited("iCaltech") | |
| Details: iCaltech headquarteredin Bangalore,BriefIndia,isengagedintheconceptualisation,development,manufacturingandmarketingofregulatoryapprovedmedicaldiagnosticproducts(primarily in respiratory). | ||
| Turnover: Refer point (j) | ||
| b) | Whether the acquisition would fallwithin related party transaction(s) | Acquisition doesn't fall within the purview of relatedparty transactions. |
| andwhetherthepromoter/ | ||
| promoter group/ group companies | None of the promoter / promotergroup / group | |
| have any interest in the entity being | companies have any interest in the entity. | |
| acquired? If yes, nature of interest | ||
| and details thereof and whether thesame is done at "arm's length" | ||
| c) | Industry to which the entity being | Healthcare,Medicalequipment&Diagnostics |
| acquired belongs | (primarily in respiratory) | |
| d) | Objects and effects of acquisition | Through this collaboration, Cipla aims tostrengthen its |
| (includingbutnotlimitedto, | partnership withiCaltechfordevelopingintegrated | |
| disclosure of reasons for acquisition | healthcare solutions andleveraging synergies between | |
| of target entity, if its business isoutside the main line of business of | pharmaceutical expertise and advanced medical devicetechnologies. | |
| the listed entity) | ||
| e) | Brief details of any governmental or | Not Applicable |
| regulatory approvals required for theacquisition | ||
| f) | Indicative time-period for completion | The investmentis expected tobe completed within 1 |
| of the acquisition | monthfrom the date of the signing of the transaction | |
| documents, or by such other date as maybe mutually | ||
| agreed between the parties. |
| g) | Nature of consideration -whether | Cash consideration |
|---|---|---|
| cash consideration or share swap and | ||
| details of the same | ||
| h) | Cost of acquisition or the price atwhich the shares are acquired | Approx. INR 5 croretowards the acquisition of 20%voting rightsthrough subscription of: |
| i) | Percentage of shareholding / control | i.1,50,820optionally convertible preference shares |
| acquired and / or number of shares | of face value of INR 10 each; and | |
| acquired | ii.1 equity shareofface value ofINR 10each. | |
| j) | Brief background about the entity | Brief Background:Refer (a) above. |
| acquired in terms of products/line of | ||
| businessacquired,dateof | History of last 3 years turnover: | |
| incorporation, history of last 3 years' | ||
| turnover,countryinwhichthe | FY 2024-25:INR 6.70 crores | |
| acquired entity has presence and any | FY 2023-24:INR 4.19 crores | |
| othersignificantinformation(in | FY 2022-23:INR 1.28 crores | |
| brief) | ||
| 10th June, 2016Date of Incorporation: | ||
| of presence: IndiaCountry |
Cipla announces investment in iCaltech Innovations to strengthen respiratory play
Deepens commitment to enhance access to advanced respiratory diagnostic solutions
Mumbai, July 21, 2025: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") announced today that it has signed definitive agreements for investment in Optionally Convertible Preference Shares of iCaltech Innovations Private Limited (hereafter referred to as "iCaltech"), subject to completion of certain conditions. iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus, with a core focus on respiratory care.
Commenting on the development, Mr. Achin Gupta, Global COO, Cipla Limited said, "As lung leaders, our decision to invest in iCaltech reflects Cipla's commitment to advancing respiratory diagnostics. With the aim to reduce the existing gap in the current ecosystem, our strategic funding will enable iCaltech to further expand and develop innovative devices. We remain committed towards providing easy access to high-quality diagnostic solutions across India."
Strategic partnerships remain central to Cipla's innovation engine, as the company continues to expand its digital, devices and diagnostics offerings and build on its legacy of lung leadership.
***
About iCaltech
iCaltech is a Bangalore based ISO 13485 certified Medical Devices Company. iCaltech conceptualises, develops, manufactures and markets Regulatory approved Medical Diagnostic Products. iCaltech aims to bring ease of access to respiratory diagnostics tests, leading to early detection and treatment, through its innovative solutions, cutting-edge research and deep expertise.
About Cipla
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, antiinfective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 74+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Mar'25), 2nd largest in the pharma prescription market in South Africa (IQVIA MAT Feb'25), and 4th largest by prescription for Generic inhalation products in the US Gx (IQVIA TRx MAT Mar'25). For almost nine decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility, and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers, and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.
Media Contacts:
Corporate Communications Investor Relations Heena Kanal Diksha Maheshwari E-Mail: [email protected] E-Mail: [email protected]